Search

Displaying results 1661 - 1670 of 10000 in total
  1. Drug

    Indium In-111 satumomab pendetide

    go.drugbank.com/drugs/DB00057
    ApprovedWithdrawn

    Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.

  2. Drug

    Haloprogin

    go.drugbank.com/drugs/DB00793
    ApprovedWithdrawn

    Haloprogin is no longer available in the United States and has been discontinued. … The mechanism of action is unknown, but it is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function.

  3. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.

  4. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    [T195] To know more about the mixture please visit [DB01049]

  5. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. … Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.

  6. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    VIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected

  7. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (

  8. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™.[L15526] … Although corticosteroids are effective in slowing disease progression in both DMD and BMD patients, they do not address the underlying molecular pathogenesis.

  9. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma

  10. Drug

    Histamine

    go.drugbank.com/drugs/DB05381
    ApprovedInvestigational

    A depressor amine derived by enzymatic decarboxylation of histidine.